Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 May 20;98(7):E1152–E1162. doi: 10.1210/jc.2013-1081

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2013 by The Endocrine Society

PMC Copyright notice

Figure 1. — Expression and localization of NR2F2 in ovarian cancer. A, NR2F2 expression is decreased in serous ovarian cancers compared with normal and benign tissues. B, NR2F2 is decreased across all histotypes of epithelial ovarian cancers. In both A and B, the relative expression of NR2F2 transcript is normalized to levels of 18s in the normal ovary. C–F, Immunohistochemical staining for NR2F2. Magnification of ×4 cores (C and E) and ×20X cores (D and F) of normal ovary with epithelial cleft (C-D) or serous ovarian cancer (E and F). G, Composite results from tissue microarray scoring. *, P < .05. Cyst, serous cystadenoma; F_epi, frequency of staining in epithelium; F_str, frequency of staining in stroma; FT, fallopian tube; I_epi, intensity of staining in epithelium; I_str, intensity of staining in stroma; OvCa, serous ovarian cancer; S, stroma. Arrows, Epithelium.